CONMED (CNMD) PT Raised to $111 at Needham & Company

Needham & Company analyst Mike Matson raised the price target on CONMED (NASDAQ: CNMD) to $111.00 (from $101.00) while maintaining a Buy rating.

The analyst comments "We believe that CNMD’s turnaround is complete and that its recent performance has proven that it can sustain high-single digit revenue growth and double-digit adjusted EPS growth. We expect CNMD to beat consensus revenue and EPS in 3Q19. We expect CNMD’s new products, AirSeal, and Buffalo Filter to drive revenue upside and expect management to allow this to flow through and drive EPS upside."

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• Lithium Ionic Corp (LTH:CN) PT Lowered to Cdn$2.50 at Desjardins
• GMR Airports Infrastructure (GMRI:IN) PT Raised to INR99 at ICICI Securities